Trials / Completed
CompletedNCT01655771
TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-1211 Dose 1 | |
| DRUG | TD-1211 Dose 2 |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-02-01
- Completion
- 2013-03-01
- First posted
- 2012-08-02
- Last updated
- 2021-01-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01655771. Inclusion in this directory is not an endorsement.